Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
Vanita R. Aroda, Lawrence Blonde, Richard E. Pratley
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 23, Iss. 5, pp. 979-994
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (PIONEER REAL Canada)
Akshay Jain, Sonja M. Reichert, Hanan Amadid, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 5, pp. 1799-1807
Open Access | Times Cited: 11
The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs
Michał Nicze, Maciej Borówka, Adrianna Dec, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 815-815
Open Access | Times Cited: 8
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
Michael J. Koren, Olivier Descamps, Yoshiki Hata, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 174-183
Closed Access | Times Cited: 7
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
Rafael Tamayo‐Trujillo, Viviana A. Ruiz‐Pozo, Santiago Cadena-Ullauri, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 7
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Jeffrey L. Cummings, Alireza Atri, Howard Feldman, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access
Applications and Challenges of Oral Peptide Drug Delivery in Diabetes Treatment
Yuchen Feng
Theoretical and Natural Science (2025) Vol. 68, Iss. 1, pp. 234-244
Open Access
Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists
Xuetao Chen, Shicheng Xu, Shuang Yang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
Xu He, Wei Zhao, Ping Li, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Recent advances, strategies, and future perspectives of peptide-based drugs in clinical applications
Qimeng Yang, Zhipeng Hu, Hongyu Jiang, et al.
Chinese Journal of Natural Medicines (2025) Vol. 23, Iss. 1, pp. 31-42
Closed Access
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wenwei Wan, Qikai Qin, Linshan Xie, et al.
Molecules (2023) Vol. 28, Iss. 2, pp. 751-751
Open Access | Times Cited: 18
Beyond glycemia: Comparing tirzepatide to GLP-1 analogues
John Andraos, Harleen Muhar, Shawn Smith
Reviews in Endocrine and Metabolic Disorders (2023) Vol. 24, Iss. 6, pp. 1089-1101
Open Access | Times Cited: 12
Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023
Si Xiong, Ruoyu Gou, Xudong Liang, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 8, pp. 1717-1733
Open Access | Times Cited: 3
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Richard E. Pratley, Zeb Saeed, Anna Casu
Current Opinion in Gastroenterology (2024) Vol. 40, Iss. 5, pp. 404-412
Closed Access | Times Cited: 3
Modified Chitosan for Highly Efficient Non‐Invasive Transdermal Delivery of Catalase to Repair and Prevent Skin Photodamages
Xiaoying Yan, Yuchun Xu, Ting Wei, et al.
Advanced Functional Materials (2024)
Closed Access | Times Cited: 2
Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs
Morten Hach, Dorthe Kot Engelund, Simon Mysling, et al.
Pharmaceutical Research (2024) Vol. 41, Iss. 10, pp. 1991-2014
Closed Access | Times Cited: 2
The role of incretin receptor agonists in the treatment of obesity
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4178-4196
Open Access | Times Cited: 1
An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database
Anca Butucă, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1124-1124
Open Access | Times Cited: 1
Enhanced Oral Efficacy of Semaglutide via an Ionic Nanocomplex with Organometallic Phyllosilicate in Type 2 Diabetic Rats
Gyu Lin Kim, Jae Geun Song, Hyo-Kyung Han
Pharmaceutics (2024) Vol. 16, Iss. 7, pp. 886-886
Open Access | Times Cited: 1
Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
Livia Basile, Rossella Cannarella, Stefano Iuliano, et al.
Minerva Endocrinology (2024) Vol. 49, Iss. 2
Closed Access | Times Cited: 1
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
Zhiqiang Ke, Qianqian Ma, Xiaonan Ye, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116471-116471
Closed Access | Times Cited: 1
The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide
Tovi Shapira‐Furman, Ayala Bar-Hai, Amnon Hoffman, et al.
Molecules (2024) Vol. 29, Iss. 16, pp. 3909-3909
Open Access | Times Cited: 1
Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer Into Human Milk
Hanin Diab, Taylor Fuquay, Palika Datta, et al.
Nutrients (2024) Vol. 16, Iss. 17, pp. 2886-2886
Open Access | Times Cited: 1
Oral Drug Delivery Systems Applied to Launched Products: Value for the Patients and Industrial Considerations
Takayuki Yoshida, Hiroyuki Kojima
Molecular Pharmaceutics (2023) Vol. 20, Iss. 11, pp. 5312-5331
Closed Access | Times Cited: 4
Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery
Seho Kweon, Jun-Hyuck Lee, Seong-Bin Yang, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 3
Effects of Oral Semaglutide on Renal Function in Diabetic Kidney Disease: A Short-term Clinical Study
Akira Mima, SAYUMI KIDOOKA, Takahiro Nakamoto, et al.
In Vivo (2023) Vol. 38, Iss. 1, pp. 308-312
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top